{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for beta root_codes_code in Code Literal (approximate match)
Status:
US Approved Rx
(1996)
Source:
BLA103628
(1996)
Source URL:
First approved in 1996
Source:
BLA103628
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(1993)
Source:
BLA103471
(1993)
Source URL:
First approved in 1993
Source:
BLA103471
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
M009
(2025)
Source URL:
First approved in 2024
Source:
M016
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT02234869: Phase 4 Interventional Withdrawn Relapsing Multiple Sclerosis
(2014)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT04595877: Phase 4 Interventional Completed Pain
(2006)
Source URL:
Class:
PROTEIN
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2012)
Source URL:
First approved in 2010
Source:
21 CFR 333D
Source URL:
Class:
STRUCTURALLY DIVERSE
